ANGOSTURA
12.2.2020 18:47:05 CET | Business Wire | Press release
The House of Angostura® has announced that world-renowned Trinidadian-born DJ, music producer and entrepreneur Christopher “Jillionaire” Leacock will add some star quality to the judging panel, and the celebration, at this year’s Angostura Global Cocktail Challenge. This biannual event, celebrates its 10th anniversary in 2020 and brings together bartenders worldwide for the chance to become the global champion. The Angostura® Global Cocktail Challenge Finals takes place on February 22 in Trinidad & Tobago, ahead of the greatest show on earth, Trinidad & Tobago Carnival.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005699/en/
Peter Sandström, CEO of Angostura® , comments: “The Angostura® Global Cocktail Challenge is the 10th anniversary of the competition and we wanted to do something special to mark the occasion. Partnering with Jillionaire made so much sense as his roots are inherently connected to the House of Angostura® . He has a strong understanding of Angostura’s place at the heart of Trinidad & Tobago culture, enormous passion for locally inspired music and drinks and his global following helps elevate the competition to showcase the extraordinary talents of our competitors to an international audience.”
The nine finalists of the Angostura® Global Cocktail Competition 2020 are: Shana Rajahram (Trinidad & Tobago), Marv Cunningham (The Bahamas), Chad Lawrence (Canada), Gustavo Costa (Brazil), Mike Jordhoy (France), Rohan Massie (Australia), Simon Dacey (United Kingdom), Vasile Dorofeev (Dubai) and Agung Satria (Vietnam).
Jillionaire, best known for his contributions to Major Lazer, an American electronic music group, brings a keen interest and understanding of the bar industry as part-owner of Clyde’s, a Trinidadian cocktail bar in Brooklyn, New York. He is well prepared to see the nine finalists compete, as they aim to wow the judges with cocktail prowess.
Jillionaire shares why he’s proud to join the Angostura® Global Cocktail Challenge judging panel: “I am a proud supporter of Trinidadian culture and have a personal interest in cocktail culture and one of our island’s biggest exporter - Angostura® . Angostura’s historic bitters are known the world over. I’m keen to shine a light on our celebrated rum and amaro which capture the flavours of Trinidad & Tobago. Whoever goes on to win the competition, will not only be representing Angostura® , they’ll be representing our island on the world stage, something I take seriously.”
Angostura Global Cocktail Competition Master of Ceremonies and Judging Panel
Jillionaire will join head judge and James Beard Award-winning beverage professional, Maxwell Britten. Other judges include Eryn Reece, Bar Director at The Wooly Public, Joe Schofield, co-owner of Schofield’s Bar, Angostura® Chief Brand Educator, Raymond Edwards, and the reigning Angostura® Global Cocktail Challenge Champion, Raymond Letoa. Hospitality industry veteran Ms Franky Marshall will serve as Master of Ceremonies. After the competition, Jillionaire will lead the after-party celebrations, performing a curated DJ set.
The winning bartender will receive the coveted title of “Angostura® Global Cocktail Challenge (AGCC) Champion,” a cash prize of US$10,000 and a two-year contract as the Angostura® Global Brand Ambassador for ANGOSTURA® aromatic bitters, ANGOSTURA® orange bitters, Angostura® Rums and Amaro di ANGOSTURA® , as well as the opportunity to revisit Angostura’s home in Trinidad & Tobago to serve as a judge at the next edition of the competition.
For more information about the competition, visit www.AngosturaGlobalCocktailChallenge.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005699/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom